TNF Superfamily Receptor Modulators Innovative Immuno-Oncology Therapeutics BioRN Lounge,
|
|
- Caren Wheeler
- 5 years ago
- Views:
Transcription
1 TNF Superfamily Receptor Modulators Innovative Immuno-Oncology Therapeutics BioRN Lounge, Dr. Juergen Gamer, VP Business Development 1
2 Overview 1 Clinical stage immuno-oncology company focusing on best-in-class protein therapeutics 2 Apogenix was founded in Spin-out of the German Cancer Research Center - Located in Heidelberg, Germany - Financed by dievini (Dietmar Hopp), licensing deals and public grants 3 Apogenix has formed a network of partners - Academic collaborations with intl. institutions - Licensing partners Abbvie & CANbridge - Service & business partners 4 Apogenix has built an attractive IO pipeline with two assets in clinical development - Asunercept (CD95L checkpoint inhibitor), positive data from PII in GB and PI in MDS - HERA-TRAIL (TRAIL receptor agonist) in Phase I study - HERA-ligands in preclinical development June 2018 Apogenix AG TNF Superfamily Modulators 2
3 Cancer and Immune System The immune system is an efficient defense mechanism to eliminate tumor cells T eff cell NK cell Immune suppressive molecules MDSC T reg cell However, under constant vigilance of the immune system, tumor cells adapt and are able to form tumors by evading the anti-tumor immune response Adapted from Yarchoan et al. Nature Review Cancer : June 2018 Apogenix AG TNF Superfamily Modulators 3
4 Implications Development PD-1 Inhibitor Nivolumab From Bench to Bedside in 22 Years Discovery & Preclinical Phase I Phase II Phase III 1992 PD-1 gene discovered at Kyoto University 1994 Inhibitors of PD-1 patented by Ono 2002 PD-L1 expressed on tumor cells Anti PD-1 mabs have preclincial anti-tumor efficacy 2006 FiH 2009 Start PII 2013 Start PIII 2014 FDA / JP approval Publications 1,346 publications PD-1/PD-L1 5 approved drugs 126 in development Clinical trials 1,269 active trials June 2018 Apogenix AG TNF Superfamily Modulators 4
5 Immunosuppression in Tumor Microenvironment Heterogeneity regarding tumor microenvironment (TME) and immune cell infiltrates in tumors is observed The pre-existing immune landscape within the TME seems to be of prognostic value in multiple malignancies CD3+ T cells (green), tumor marker (magenta) Lieke et al. Trends in Cancer, November 2017, Vol. 3, No. 11 June 2018 Apogenix AG TNF Superfamily Modulators 5
6 TNF Receptor Superfamily in Cancer Therapy Members of the TNF receptor/ligand family are key modulators of the immune response and attractive targets in immuno-oncology Apogenix TNF SF modulators are ideal candidates for combination with other IO approaches such as cancer vaccines, cell therapies or checkpoint inhibitors Receptor Agonists HERA-Ligands 4-1BB Antigen presentation OX40 and immune cell GITR activation LIGHT CD27 CD40 CD40 Trafficking of tumor antigens to the lymph node T cells Lymph node Blood vessel Adoptive Cell Therapies Cancer Vaccines (e.g. mrna) TRAIL Direct killing of tumor cells Tumor PD-1 Ligand CD95 Ligand Kills activated immune cells (AICD) CD95L Inhibitor Asunercept PRIME Status June 2018 Apogenix AG TNF Superfamily Modulators 6
7 HERA-Ligands June 2018 Apogenix AG TNF Superfamily Modulators 7
8 First Generation TNF SF Receptor Agonists: TNFR SF Receptor Antibodies Have a Complex MoA Binding of a trimeric ligand induces TNF SF receptors multimerisation, thereby triggering receptor activation Anti-tumor efficacy of agonistic antibodies is based on a complex mixture of FcR-mediated activities inducing opposite effects and potential safety issues Nature Monomeric mabs have low agonistic activity Agonistic mabs induce multiple activities Clustering Backsignaling Stimulation Stimulation CD40 TNF SF Ligands TNF SF Receptors Immune Cell a-dr5 mab monomer a-dr5 mab aggregates 1 a-dr5 mab aggregates 2 Cell viability assay of cancer cells with fractionated anti-trailreceptor antibodies Stimulation ADCC CDC Gieffers et al. Mol Cancer Ther; 12(12) December 2013 June 2018 Apogenix AG TNF Superfamily Modulators 8
9 VL VL NH 2 HERA-Ligands Best-In-Class TNF Receptor SF Agonists Goal: Design a receptor agonist with defined, stabilized trimerization capabilities This versatile platform allows realization of various agonistic protein formats Apogenix HERA-ligands mechanism of action purely relies on their potent agonistic activity HERA-ligands HERA-ligands Design HERA-ligands have potent agonistic activity Next generation HERA-ligands HERA-TRAIL / ABBV621 COOH COOH C H3 C H3 C H2 C H2 NH 2 Singlechain TNF SF Ligand HERA- TRAIL + xlink HERA-TRAIL (monomer) NH2 V L V H NH 2 COOH COOH COOH COOH C H3 C H3 C H3 C H3 COOH C L C H1 COOH COOH NH 2 NH 2 COOH NH 2 C H2 C H2 NH 2 NH2 C L COOH NH C H2 C 2 H2 NH 2 V H C H1 V H C H1 C L COOH NH2 Cell viability assay of cancer cells with monomeric HERA-ligands Stimulation Trivalent, Targeting Hexavalent, non-fc Hexavalent Fc Hexavalent Fc Targeting Gieffers et al. Mol Cancer Ther; 12(12) December 2013 June 2018 Apogenix AG TNF Superfamily Modulators 9
10 HERA-Ligands Production HERA-ligands are produced as homogenous, non-aggregating proteins in physiological buffers 4-1BBL Features: Hexavalent TNF receptor agonists, kd Production process: CHO based fed batch suspension culture Receptor interaction: Verified by various methods (ELISA*, QCM*, FACS*) Analytics prior to biological characterization: Endotoxin, residual DNA-content, host cell protein *QCM: Quartz Crystal Microbalance; FACS: fluorescence-activated cell scanning; ELISA: Enzyme-linked Immunosorbent Assay June 2018 Apogenix AG TNF Superfamily Modulators 10
11 HERA-Ligands Receptor Binding All HERA-ligands bind specifically to the immobilized receptor ELISA* assays rely on functional binding to coated recombinant receptors ELISA data were confirmed by cellular receptor binding assays (FACS*) *FACS: fluorescence-activated cell scanning; ELISA: Enzyme-linked Immunosorbent Assay June 2018 Apogenix AG TNF Superfamily Modulators 11
12 CD206 (log scale) Cell number Ikbα positive cells [%] Ikbα positive cells [%] HERA-CD40L Stimulation of B cell Activation & Survival B cells + HERA-CD40L Activation Survival HERA-CD40L induces NF-kB signaling in B cells independent of crosslinking HERA-CD40L time [min] crosslink + crosslink 0 αcd40 mab HB time [min] HERA-CD40L shifts monocytes to anti-tumorigenic M1-like macrophages CD40-expressing Ramos B cells were treated with 100 ng/ml HERA-CD40L or 5 μg/ml anti-cd40 mab (HB14 or G28.5) either alone or in the presence of a crosslinking agent. Medium HERA-CD40L αcd40mab 5C3 αcd40mab HB14 Monocytes + HERA-CD40L Compound Medium M2-like Macrophages Antitumorigenic Protumorigenic M1-like Macrophages CD54: ICAM 1 (log scale) M2: 76% M1: 18% M2: 22% M1: 61% M2: 66% M1: 27% M2: 68% M1: 26% Apogenix compounds (100ng/ml) or antibodies (1µg/ml, mouse IgG1,k) added on 0d. Analysis 3d. CD163 (log scale) June 2018 Apogenix AG TNF Superfamily Modulators 12
13 HERA-CD40L Treatment Increases T Cell Infiltration HERA-CD40L impairs tumor growth in syngeneic MC38-CEA model Therapy was started on day 5 after tumors reached 100mm 3. HERA-CD40L (1mg/kg 2qW). HERA-CD40L promotes infiltration of T cells in a syngeneic CT26wt model Tumour size (day 24) Infiltration of T cells (day 24) Therapy was started on day 14 after tumors reached 100mm 3. HERA-CD40L (2qW) PBS HERA-CD40L 1 mg/kg HERA-CD40L 10 mg/kg June 2018 Apogenix AG TNF Superfamily Modulators 13
14 HERA-Ligands Best-In-Class TNFR Agonists HERA-ligands act via well characterized MoA with superior efficacy over antibodies HERA-ligands consistently boost antigen-specific immune cell activity across cell types and antigens without affecting the non-specific immune cells HERA-ligands show strong anti-tumor efficacy in vitro and in vivo HERA-CD27L, -CD40L, -GITRL: Safe and well tolerated in a pilot monkey tox study Lead candidates selected in cell line development show high productivity June 2018 Apogenix AG TNF Superfamily Modulators 14
15 Asunercept June 2018 Apogenix AG TNF Superfamily Modulators 15
16 Tumor Escape from the Immune System Tumors establish an immune-cell barrier to escape from the immune attack CD95L is one of the key defense mechanisms T cells Courtesy of Prof. Dr. Jäger, NCT Heidelberg June 2018 Apogenix AG TNF Superfamily Modulators 16
17 CD95 Ligand An Immune Checkpoint Physiological Role of CD95L Homeostasis of Immune Response CD95L induces apoptotic T cell death CD95L induces apoptotic T cell death by activation-induced cell death (AICD) CD95L-mediated AICD is an important mechanism to establish immune homeostasis and has been described in more than 600 publications since 1993 Role of CD95L in Solid Tumors Lung cancer (NSCLC) 52% Pancreatic cancer 51% Melanoma 24% Ovarian cancer 50% Glioblastoma 66% Head & neck cancer 30% Gastric cancer 41% Renal cancer Colon cancer 47% 20% CD8 + T cells in human ovarian cancer tissue CD95L positive patient CD95L negative patient Motz et al, Nat Med Jun;20(6): CD95L is expressed by various cell types in the tumor microenvironment thereby protecting tumor cells from immune attack Motz et al. showed that CD95L expressed in the tumor correlates with reduced amounts of CD8 positive T cells June 2018 Apogenix AG TNF Superfamily Modulators 17
18 CD95 Signaling in Tumor Physiology Recent publications point towards a major role of CD95L/FasL in the tumors immune escape June 2018 Apogenix AG TNF Superfamily Modulators 18
19 CD95 Signaling in Tumor Microenvironment Upregulation of CD95L in the tumor mircroenvironment forms a deadly barrier for activated T cells CD95L (endothelial cells) CD95L (MDSCs) CD95L (tumor associated fibroblasts) Van der Woude et al. Trends in Cancer, November 2017, Vol. 3, No. 11 June 2018 Apogenix AG TNF Superfamily Modulators 19
20 Apoptosis Sensitivity (RFU) Asunercept Inhibition of CD95L-Mediated Cell Death Asunercept inhibits sensitivity of primary human immune cells to CD95L-induced killing CD95L induces death of activated T cells derived from human PBMCs Asunercept inhibits CD95L-mediated immune cell death Human PBMCs PBMC donor #1 PBMC donor #2 CD95 acd3/ acd28 PBMC donor #3 Fc IgG1 Activated T cell CD95L Medium 20 ng/ml 100 ng/ml 500 ng/ml CD95 ligand 500 ng/ml CD95L 5 mg/ml Asunercept 500 ng/ml CD95L 5 mg/ml APG122 T cell death CD95L dose-dependently induced apoptotic cell death of activated immune cells Asunercept (CD95-Fc) blocks apoptosis of activated immune cells Non functional APG122 (CD95-Fc derivative R87S point mutation) has no effect on immune cell apoptosis June 2018 Apogenix AG TNF Superfamily Modulators 20
21 Results Study Design Positive Results from Controlled Phase II Study in Glioblastoma Recurrent GB Patients (n=84) (n=58) Randomization (2:1) (n=26) Radiotherapy (18x 2 Gray) + Asunercept weekly i.v.; 400mg Radiotherapy (18x 2 Gray) No further treatment Safety: Excellent safety profile and very good tolerability Efficacy: All clinical endpoints were reached Endpoint Asunercept / RT RT only P value PFS6 21% 4% p=0.048 Median PFS 4.5 months 2.5 months p=0.016 mos (per protocol) 13.2 months 11.5 months p=n.s. mos (CD95L biomarker) 16.2 months 7.7 months p= year OS N=4 (6.9%) N=0 Based on the PII data, asunercept received PRIME Status (July 2017) EMA opened pathway to accelerated approval June 2018 Apogenix AG TNF Superfamily Modulators 21
22 Myelodysplastic Syndromes (MDS) Myelodysplastic syndromes (MDS) are clonal hematologic malignancies that are characterized by ineffective hematopoiesis, resulting in anemia CD95 has a key role in mediating hematopoietic commitment and homeostasis Standard Therapy MDS Patients (Low-int1 risk) EPO 70% 30% EPO Non-Responder EPO Refractory EPO Responder No therapeutic option, only red blood cell transfusions June 2018 Apogenix AG TNF Superfamily Modulators 22
23 MDS Patient Hematopoiesis Asunercept in PI Study MDS Patients Summary Asunercept Asunercept Hematopoietic stem cell BFU-E* Reticulocyte Erythrocyte Asunercept Transfusions CD95L involvement Asunercept treatment was well tolerated. Mechanism of action proposed by preclinical studies could be confirmed. Short-term treatment with asunercept improved erythropoiesis (BFU-Es, reticulocytes). In highly transfusion-dependent MDS patients (7-16 transfusions/12weeks) asunercept decreased the number of required RBC transfusions in 47% of the patients. Treatment effect of asunercept was dose-dependent. A better response rate was observed in the 400mg dose group (66%) compared to the 100mg dose group (36%). June 2018 Apogenix AG TNF Superfamily Modulators 23
24 Summary Attractive and diversified IO pipeline with two assets in clinical development PRIME Status granted from EMA paves the way for accelerated approval in EU PROGRAM INDICATION Preclinical Phase I Phase II Phase III Partner Asunercept (CD95L inhibitor) 2nd line Glioblastoma 1st line Glioblastoma Myelodysplastic Syndromes PRIME STATUS PRIME STATUS (China) Solid Tumors HERA-TRAIL HERA-CD40L HERA-CD27L HERA-GITRL HERA-HVEML Hematologic & Solid Tumors HERA-OX40L HERA-4-1BBL June 2018 Apogenix AG TNF Superfamily Modulators 24
25 Heidelberg, Germany Apogenix AG Im Neuenheimer Feld 584 D Heidelberg Germany Telephone +49 (0) Fax +49 (0) June 2018 Apogenix AG TNF Superfamily Modulators 25
Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationIdentification of novel immune regulators of tumor growth using highthroughput
Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationDISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d
nanostring.com/3d DISCOVER MORE WITH LESS SAMPLE. WHY COMPROMISE? ncounter Vantage ASSAYS POWERED BY 3D BIOLOGY TECHNOLOGY Don t let sample volume limit your analytical aspirations. Quantify DNA, RNA,
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationExploring the PD-L1 Pathway
Active Within the tumor microenvironment Steps 1-3: Initiating and propagating anticancer immunity 1 may inhibit T-cell activity in the tumor microenvironment Dendritic cells capture cancer and then prime
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationHeat Biologics. Corporate Presentation March 9, 2018
Heat Biologics Corporate Presentation March 9, 2018 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements within the meaning of the Private
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationTMAC Affimer Drug Conjugates
TMAC Affimer Drug Conjugates A novel and proprietary class of immuno-oncology active, dual mode of action drug conjugates PRS 001 Immune-checkpoint Therapies: Improving Patient Response Rates Despite great
More informationEnhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine
Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics SMI Cancer Vaccines, September 2017 Nektar Therapeutics
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationIMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018
NEXT NEXT GENERATION GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY CHI Immuno-oncology Summit Boston 27 th August 2018 2 Safe harbor Any statements contained herein that are not statements
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationDaratumumab: Uncovering a novel mechanism of action for an approved antibody therapy
Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma
More informationA Versatile Tool to Study Immune Checkpoint Therapeutics: Syngeneic Tumor Mouse Models in vivo
The Solution Provider for Drug Discovery in Oncology A Versatile Tool to Study Immune Checkpoint Therapeutics: Syngeneic Tumor Mouse Models in vivo Holger Weber - 1 - Drug discovery platform for oncology
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationA NEW FRONTIER IN IMMUNO-ONCOLOGY
A NEW FRONTIER IN IMMUNO-ONCOLOGY Proactive One2One Forum London, March 8 th 2018 Dr Richard Goodfellow LSE: SCLP.L CLINICAL STAGE IMMUNO-ONCOLOGY COMPANY Scancell is developing innovative immunotherapies
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationWe re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationDual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast NALM-6 tumor cells (B-ALL) Human macrophages
Dual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast Krzysztof Masternak, PhD, Head of Biology 1 2 nd Biologics & BOARD Biosimilars MEETING Congress MARCH 2012 NALM-6
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationABBVIE VENTURES VISION. Drive strategic returns to AbbVie as a key constituent of overall corporate strategy
ABBVIE VENTURES ABBVIE VENTURES VISION Drive strategic returns to AbbVie as a key constituent of overall corporate strategy Early access to external innovation with a long-term horizon to generate meaningful
More informationCowen Health Care Conference
Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationCopyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
More informationImmune Checkpoint Proteins
Immune Checkpoint Proteins www.acrobiosystems.com Content I. Introduction II. Biotinylated Immune Checkpoint Proteins III. PD1:PDL1 Inhibitor Screening Assay Kit IV. HPLC-Verified Checkpoint Proteins V.
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationA Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs. European Business Development Conference Düsseldorf 24 Sept 2013
A Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs European Business Development Conference Düsseldorf 24 Sept 2013 Key facts about NOXXON Developing a new class of proprietary
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationTGFβR1 Kinase Inhibitor
TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Derived from Prud homme GJ 1 ; Flavell RA, et al. 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationWe want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target
We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1 Safe Harbour Statement The following
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationNovità nelle MDS. Matteo G Della Porta. Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy
Novità nelle MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu Outline ARCH Predictive value of somatic
More informationOncoMed Pharmaceuticals Jefferies Healthcare Conference. Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016
OncoMed Pharmaceuticals Jefferies Healthcare Conference Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016 Safe Harbor Statement These slides and accompanying oral presentation
More informationVenky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA
Antibody Targeting of Human CD27 with Varlilumab (CDX-1127) identifies genes and pathways related to inflammation Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA www.celldextherapeutics.com
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCorporate Presentation
Corporate Presentation October 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine s current expectations
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationTherapeutic Targets of the TNF Superfamily
Therapeutic Targets of the TNF Superfamily Edited by Iqbal S. Grewal, PhD Department of Preclinical Therapeutics, Seattle Genetics, Inc., Bothell, Washington, USA Springer Science+Business Media, LLC Landes
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationPD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs
PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs Steven Dow, DVM, PhD Department of Clinical Sciences, Animal Cancer Center Colorado State University Consortium
More informationNovel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist Promega Corporation
Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist 215 Outline Immune Checkpoint and Combination Therapies Reporter Gene Bioassays: Design,
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationPersonalized Cancer Neoantigen Vaccines
Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More information